Sunday, November 13, 2016

Dr. Reddy's Laboratories announces the launch of Raloxifene HCl Tablets, USP in the U.S. Market

Hyderabad, India, 11 November 2016                                                                                                       

Hyderabad, India and Princeton, NJ, USA. 11 November 2016 - Dr. Reddy’s Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has launched Raloxifene hydrochloride tablets in 60 mg, a therapeutic equivalent generic version of Evista®(raloxifene hydrochloride) tablets in the United States market, approved by the U.S. Food & Drug Administration (USFDA).

The Evista® brand and generic had U.S. sales of approximately $265 million MAT for the most recent twelve months ending in September 2016 according to IMS Health*.

Dr. Reddy’s Raloxifene tablets are available in 60 mg in bottle count sizes of 30, 100 and 1,000.

Evista® is a registered trademark of Eli Lilly and Company.

*IMS National Sales Perspective: Retail and Non-Retail MAT September 2016

No comments:

Post a Comment